FROM HOPE TRIAL TO ONTARGET TRIAL: THE «HOPE» TO REACH THE «TARGET» - TO IMPROVE PROGNOSIS IN HIGH RISK PATIENTS

Results of HOPE trial are analyzed. It is noted, that treatment with angiotensine converting enzyme inhibitor (iACE) ramipril improves the prognosis in high risk cardio-vascular patients. The objectives and study design of ONTARGET/TRANSCEND trials are introduced. Perspectives of joint use of ACE in...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: Yu. M. Lopatin
Médium: Artigo
Jazyk:Inglês
Vydáno: Stolichnaya Izdatelskaya Kompaniya 2016-01-01
Edice:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Témata:
high cardio-vascular risk
ramipril
telmisartan
норе trial
ontarget trial
On-line přístup:https://www.rpcardio.com/jour/article/view/1052
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky